⚕ GalenOps field
←

SITE012-0277

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE012 (BRA) · Dr. Kowalski
consented 2023-01-26

AEs
8
Serious
0
Dropout signal
–

Adverse events

moderate assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-02-10 (study day 2); relationship: not assessed

mild assessed

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-02-10 (study day 2); relationship: not assessed

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-02-10 (study day 2); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-10 (study day 2); relationship: not assessed

mild assessed

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-02-10 (study day 2); relationship: N

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-02-10 (study day 2); relationship: N

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-02-10 (study day 2); relationship: N

moderate assessed

Grade 2 Rash — outcome: RECOVERED/RESOLVED; onset 2023-02-13 (study day 5); relationship: not assessed

Data queries

No data queries.